CellCarta Launches Global Digital Pathology and AI Consortium to Give CRO Sponsors Platform-Agnostic Access to Leading AI Innovators

• CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, has announced the launch of its Global Digital Pathology and AI Consortium — a curated, AI-agnostic ecosystem of seven founding digital pathology and precision diagnostics technology partners designed to give biopharma sponsors a single CRO-led pathway to evaluate, validate, and deploy advanced AI capabilities across oncology, autoimmune, neurodegenerative, and other disease areas.

• The Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix, and Indica Labs within CellCarta’s global histopathology, genomics, immunology, proteomics, sample logistics, data analysis, and regulatory infrastructure — extending CellCarta’s platform-agnostic operating model into digital pathology and AI to help sponsors move from exploratory AI signals to clinical-trial-ready evidence without fragmented vendor relationships.

CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, announced on July 15, 2026, from Montreal, Canada, the launch of its Global Digital Pathology and AI Consortium — a curated, non-exclusive, modular ecosystem of leading digital pathology, artificial intelligence, and precision diagnostics innovators integrated within CellCarta’s global CRO laboratory infrastructure. The Consortium is designed to give biopharma sponsors a single, scientifically credible, operationally controlled path to evaluate and apply AI-enabled digital pathology capabilities across drug development programs spanning biomarker discovery, patient stratification, clinical trial execution, and companion diagnostic strategy.

Seven founding technology partners join CellCarta in the initial Consortium formation. Lunit contributes clinically validated AI for immune phenotyping, tumor microenvironment biomarker generation from H&E, IHC quantification, and H&E-based molecular state prediction. Mindpeak provides tissue AI for precision oncology, converting IHC, H&E, and multiplex immunofluorescence images into quantitative insights from biomarker discovery through companion diagnostic rollout. Imagene AI delivers multimodal foundation models and real-world data for biomarker discovery, patient stratification, and response prediction. Dipath AI brings AI-assisted digital pathology solutions with deep China market presence. Nucleai provides AI-based tissue intelligence with a specific track record in ADC clinical programs and clinical trial application development under quality management systems. Tivenix extends the Consortium’s reach into AI-enabled bioinformatics and liquid biopsy, using methylation biomarker data to assess organ-specific cell-death signals for early detection and stratification of neurodegenerative conditions. Indica Labs contributes AI-powered digital pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development.

For CRO clients, the Consortium’s defining structural feature is its AI-agnosticism. Rather than committing sponsors to a single algorithm or AI vendor pathway, the model gives sponsors the flexibility to evaluate and select the most appropriate AI approach for each specific program — guided by CellCarta’s pathologist-directed workflows, whole-slide scanning, image analysis, assay development, clinical laboratory operations, and regulatory experience. The Consortium integrates directly with CellCarta’s existing capabilities across histopathology, genomics, immunology, proteomics, spatial biology, and CDx services, enabling AI-enabled analyses to be embedded within — rather than bolted onto — established laboratory and regulatory workflows that sponsors already rely on for clinical trial execution.

The launch addresses a structural challenge that has emerged as AI in pathology has rapidly proliferated: sponsors have access to a growing number of AI-enabled pathology tools, but lack an operationally coherent framework for evaluating them against real program data, validating their performance in GxP-controlled settings, and deploying them within regulatory submissions. CellCarta’s Consortium model positions the CRO as the integrating layer — connecting AI innovation with the laboratory operations, pathologist oversight, quality systems, and regulatory expertise required to make AI-generated insights clinically and regulatorily actionable. The Consortium is expected to expand over time as new technologies mature, additional disease areas emerge, and sponsors require more integrated approaches to digital pathology, AI, and multi-omic biomarker development.

“AI in pathology is moving quickly, but sponsors do not need another black box or another fragmented vendor pathway. They need a scientifically credible, operationally controlled way to evaluate, validate and deploy the right AI approach for the right program. CellCarta’s Digital Pathology and AI Consortium give sponsors a single CRO laboratory partner that understands histopathology, genomics, immunology, proteomics, digital pathology and companion diagnostics while remaining open and independent across AI platforms.”

Christopher Ung, Chief Scientific Business Officer, CellCarta